From Novo Holding's purchase of Catalent to BMS's Karuna acquisition, here are 10 of the most significant M&A moments of 2024.

Results of peer-reviewed analysis of more than 66,000 members show the positive impact Found program can have on weight loss.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.

From Ozempic butt to Ozempic for kids, semaglutide drugs are everywhere causing a whole host of concerns alongside their ...

There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...

The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

Baron India Fund declined in the fourth quarter of 2024, outperforming its benchmark, the MSCI AC Asia ex Japan/India Linked Index. Read more here.

市场对包括 Ozempic 和 Wegovy 等流行品牌在内的减肥药物的需求持续上升。 最近的一项研究显示，八分之一的美国人曾经或正在使用这些药物来控制糖尿病、心脏病或肥胖症。这些药物被正式归类为胰高血糖素样肽-1 受体激动剂（GLP-1RA），包括 ...

In a candid conversation on her podcast, Oprah Winfrey shared how she once believed that people who maintained a thin figure had more willpower ...

All these years I thought that thin people — those people — just had more willpower,” Winfrey said on her podcast.